Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.

Treatments for dual diagnosis

What is dual diagnosis?

Many treatments have been targeted to improving symptom severity for people suffering schizophrenia in combination with substance use problems. Studies of dual diagnosis often investigate the effectiveness or availability of treatments for improving outcomes relating to either diagnosis, for example symptom severity, social function, quality of life, substance use, or cognitive outcomes.

 

What is the evidence for pharmaceutical treatments for dual diagnosis?

Moderate to low quality evidence suggests olanzapine may be effective for reducing cocaine use in people with schizophrenia. Low quality evidence is unable to determine the benefits of risperidone for cannabis use, risperidone, haloperidol, chlorpromazine, aripiprazole, or mazindol for cocaine use, and lamotrigine, antidepressants, anti-craving agents, or disulfiram for substance-dependence.

Also see the Course and Outcomes drug and alcohol use topic, the Risk Factor substance use topic, the Living with Multiple Conditions drug and alcohol use topic, and the Psychosocial Treatments for dual diagnosis topic.

September 2016

Page last updated: 2:26  31 December 2017

To view documentation related to this topic download the files below